Preparation and characterization of spironolactone nanoparticles by antisolvent precipitation

International Journal of Pharmaceutics

Volumn 375, Issue 1-2, 2009, Pages 84-88

  Dong, Yuancai ^a   Ng, Wai Kiong ^a   Shen, Shoucang ^a   Kim, Sanggu ^a   Tan, Reginald B H ^a,b  

^a INSTITUTE OF CHEMICAL AND ENGINEERING SCIENCES   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Antisolvent precipitation; Dissolution rate; HPMC; NMP; Oral bioavailability; Spironolactone

Indexed keywords

1 METHYL 2 PYRROLIDINONE; HYDROXYPROPYLMETHYLCELLULOSE; NANOPARTICLE; SPIRONOLACTONE; SURFACTANT;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG SOLUBILITY; DRUG STRUCTURE; INFRARED SPECTROSCOPY; MORPHOLOGY; PARTICLE SIZE; PRECIPITATION; PRIORITY JOURNAL;

BIOLOGICAL AVAILABILITY; CRYSTALLIZATION; DIURETICS; EXCIPIENTS; METHYLCELLULOSE; NANOPARTICLES; PARTICLE SIZE; PRECIPITATION; PYRROLIDINONES; SOLUBILITY; SOLVENTS; SPIRONOLACTONE; SURFACE-ACTIVE AGENTS;

EID: 67349203808     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2009.03.013     Document Type: Article

References (21)

1. Agafonov V., Legendre B., Rodier N., Wouessidjewe D., and Cense J.-M. Polymorphism of spironolactone. J. Pharm. Sci. 80 (1991) 181-185
2. Berbenni V., Marini A., Bruni G., Maggioni A., Riccardi R., and Orlandi A. Physico-chemical characterisation of different solid forms of spironolactone. Thermochim. Acta 340-341 (1999) 117-129
3. China Pharmacopeia. Spironolactone (2005) p. 886
4. Clarke J.M., Ramsay L.E., Shelton J.R., Tidd M.J., Murray S., and Palmer R.F. Factors influencing comparative bioavailability of spironolactone tablet. J. Pharm. Sci. 66 (1977) 1429-1432
5. EI-Shabouri M.H. Nanoparticles for improving the dissolution and oral bioavailability of spironolactone, a poorly-soluble drug. STP Pharm. Sci. 12 (2002) 97-101
6. Espeau P., Nicolaï B., Céolin R., Perrin M.-A., Zaske L., Giovannini J., and Leveiller F. Thermal behavior of orthorhombic polymorphs I and II of spironolactone. J. Therm. Anal. Calorim. 90 (2007) 341-342
7. Hodges L.A., Elkordy A.A., and Mullen A.B. Dissolution enhancement of spironolactone by in situ lyophilisation. J. Pharm. Pharmacol. 58 (2006) A14
8. Keck C.M., and Muller R.H. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenization. Eur. J. Pharm. Biopharm. 62 (2006) 3-16
9. Kesisoglou F., Panmai S., and Wu Y. Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv. Drug Deliv. Rev. 59 (2007) 631-644
10. Langguth P., Hanafy A., Frenzel D., Grenier P., Nhamias A., Ohlig T., Vergnault G., and Spahn-Langguth H. Nanosuspension formulation for low-soluble drugs: pharmacokinetic evaluation using spironolactone as model compound. Drug Dev. Ind. Pharm. 31 (2005) 319-329
11. Levy G. Availability of spironolactone given by mouth. Lancet 2 (1962) 723-724
12. Liversidge G.G., and Conzentino P. Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int. J. Pharm. 125 (1995) 309-313
13. Liversidge G.G., and Cundy K.C. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int. J. Pharm. 125 (1995) 91-97
14. Losowsky M.S. Improved bioavailability from a spironolactone beta-cyclodextrin complex. Eur. J. Clin. Pharmacol. 40 (1991) 507-511
15. McInnes G.T., Asbury M.J., Ramsay L.E., Shelton J.R., and Harrison I.I. Effect of micronization on the bioavailability and pharmacologic activity of spironolactone. J. Clin. Pharmacol. 22 (1982) 410-417
16. Merisko-Liversidge E., Liversidge G.G., and Cooper E.R. Nanosizing: a formulation approach for poorly-water-soluble-compounds. Eur. J. Pharm. Sci. 18 (2003) 113-120
17. Matteucci M.E., Hotze M.A., Johnston K.P., and Williams III R.O. Drug nanoparticles by antisolvent precipitation: mixing energy versus surfactant stabilization. Langmuir 22 (2006) 8951-8959
18. Rabinow B.E. Nanosuspensions in drug delivery. Nat. Rev. 3 (2004) 785-796
19. Soliman O.A.E., Kimura K., Hirayama F., Uekama K., El-Sabbagh H.M., El-Gawad A.E.-G.H.A., and Hashim F.M. Amorphous spironolactone-hydroxypropylated cyclodextrin complex with superior dissolution and oral bioavailability 149 (1997) 73-83
20. Uchino T., Yasuno N., Yanagihara Y., and Suzuki H. Solid dispersion of spironolactone with porous silica prepared by the solvent method. Pharmazie 62 (2007) 599-603
21. Yusuff N.T., York P., Chrystyn H., Bramley P.N., Swallow R.D., and Tuladhar B.R. Improved bioavailability from a spironolactone beta-cyclodextrin complex. Eur. J. Clin. Pharmacol. 40 (1991) 507-511